Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q1 2020 · 10-Q
Revenue$164.00M$164.00M−24.3% vs Q1 2019 Net Income-$115.20M-$115.20MN/M vs Q1 2019 EPS Diluted-$1.55-$1.55N/M vs Q1 2019 Operating Income-$133,700,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Free Cash Flowderived$13,800,000+294.3% Margins · derivedOperating margin-81.5%−84.2 pt vs Q1 2019
Net margin-70.2%−73.4 pt vs Q1 2019
ended Mar 31, 2020 · filed May 6, 2020 · 36 d after period end